HDM201
Total Payments
$1.2M
Transactions
16
Doctors
1
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $214,129 | 3 | 0 |
| 2019 | $63,070 | 4 | 0 |
| 2018 | $365,395 | 3 | 0 |
| 2017 | $590,545 | 6 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.2M | 16 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| MOLECULAR ANNOTATION FOR THE TREATMENT OF CHILDHOOD CANCER TRIAL NEUROBLASTOMA | Novartis Pharmaceuticals Corporation | $765,973 | 0 |
| A PHASE I OPEN LABEL MULTICENTER DOSE ESCALATION STUDY OFORAL HDM201 IN ADULT PATIENTS WITH ADVANCED SOLID AND HEMATOLOGICAL TUMORS CHARACTERIZED BY WILD TYPE TP53 | Novartis Pharmaceuticals Corporation | $341,883 | 0 |
| A PHASE IB, MULTI-ARM, OPEN-LABEL, STUDY OF HDM201 IN COMBINATION WITH MBG453 OR VENETOCLAX IN ADULT SUBJECTS WITH ACUTE MYELOID LEUKEMIA (AML) OR HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS) | Novartis Pharmaceuticals Corporation | $125,139 | 0 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $143.25 | 1 |
Top Doctors Receiving Payments for HDM201
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New York, NY | $1.2M | 15 |
| , M.D | Internal Medicine | New York, NY | $143.25 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.2M
- Total Doctors 1
- Transactions 16
About HDM201
HDM201 is a drug associated with $1.2M in payments to 1 healthcare providers, recorded across 16 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $214,129 was paid across 3 transactions to 0 doctors.
The most common payment nature for HDM201 is "Unspecified" ($1.2M, 100.0% of total).
HDM201 is associated with 4 research studies, including "MOLECULAR ANNOTATION FOR THE TREATMENT OF CHILDHOOD CANCER TRIAL NEUROBLASTOMA" ($765,973).